23 Feb Mammoth Biosciences
Peter Nell, Ph.D., Chief Business Officer and Head of Therapeutics
Oct. 14 | 9:15am | BlueRock Therapeutics Ballroom
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. With a distinguished team, including co-founder and Nobel Laureate Jennifer Doudna, Mammoth is discovering novel CRISPR systems enabling the full potential to read and write the code of life. Mammoth’s efforts are focused on CRISPR-based diagnostics applying its proprietary DETECTR™ platform, and on differentiated gene editing approaches towards ex vivo and in vivo therapeutics benefiting from our proprietary CRISPR systems with unique characteristics. The company is establishing a pipeline of partnered and in-house programs to advance disease detection and treatment.